Post-hoc Analysis of Pegcetacoplan Phase III Study in CKD Dialysis Patients with Anemia Presented at ASN Kidney Week 2024

The 2024 American Society of Nephrology Annual Meeting (ASN Kidney Week) was held at the San Diego Convention Center in the United States from October 23 to 27 local time. The post-hoc analysis results of the Phase III study of Hansoh Pharma's self-developed Class 1 innovative drug Pemoxaplat (brand name: Shengluolai) for treating anemia in chronic kidney disease (CKD) dialysis patients were presented at the conference in poster form.

The ASN Annual Meeting is the world's premier academic conference in the field of nephrology, aimed at sharing and discussing the latest research advances and cutting-edge hot topics in kidney diseases. The 2024 meeting attracted more than 12,000 kidney care professionals from around the globe. Pemodapeptide is a novel long-acting polyethylene glycol (PEG)-ylated erythropoietin (EPO) mimetic peptide, which was approved for marketing by the National Medical Products Administration (NMPA) in June 2023 for the treatment of anemia caused by chronic kidney disease (CKD) and was included in the national medical insurance catalog in the same year.

Previously, eClinicalMedicine, a Lancet subsidiary journal, published a Phase III clinical trial of Pemotecan in CKD dialysis patients with anemia. This randomized, multicenter, open-label, non-inferiority study confirmed that Pemotecan has definitive efficacy and good safety in treating anemia in CKD dialysis patients, with patients only requiring once-monthly subcutaneous injections to achieve stable hemoglobin targets.

The Phase III post-hoc analysis results of pemodasertib in treating anemia in CKD dialysis patients, released at this year's ASN conference, further confirmed that pemodasertib is more effective than short-acting erythropoietin in achieving hemoglobin target levels and has a better safety profile.